













## Claims


1. A compound represented by the formula:



a pharmacologically acceptable salt thereof or hydrates thereof.

In the formula,  $\text{R}^1$  represents any group selected from the groups represented by the formulae:






(wherein  $(R^3)$ s are the same as or different from each other and each represents hydrogen atom, a halogen atom, hydroxyl group, a  $C_{1-6}$  alkyl group, a  $C_{3-8}$  cycloalkyl group, a  $C_{1-6}$  alkoxy group, a  $C_{1-6}$  alkoxyalkoxy group, a halogeno  $C_{1-6}$  alkyl group, a hydroxy  $C_{1-6}$  alkyl group, a cyano  $C_{1-6}$  alkyl group, an amino  $C_{1-6}$  alkyl group, a halogeno  $C_{1-6}$  alkoxy group, a hydroxy  $C_{1-6}$  alkoxy group, a cyano  $C_{1-6}$  alkoxy group, a lower acyl group, nitro group, an optionally substituted amino group, an optionally substituted carbamoyl group, mercapto group or a  $C_{1-6}$  thioalkoxy group;  $R^4$  represents hydrogen atom or a  $C_{1-6}$  alkyl group;  $R^5$  represents a halogen atom (provided that fluorine is excluded), hydroxy group, a  $C_{1-6}$  alkyl group, a  $C_{1-6}$  alkoxy group, cyano group, a halogeno  $C_{1-6}$  alkyl group, a hydroxy  $C_{1-6}$  alkyl group, a cyano  $C_{1-6}$  alkyl group, an amino  $C_{1-6}$  alkyl group, nitro group, an azido group, an optionally substituted amino group, an optionally substituted carbamoyl group, an optionally substituted carboxyl group, mercapto group or a  $C_{1-6}$  thioalkoxy group; the partial structure  $---$  represents a single bond or double bond;  $m$  is 0 or an integer from 1 to 6;  $n$  is an integer from 1 to 4;


and p is an integer of 1 or 2); and

$R^2$  represents a  $C_{3-8}$  cycloalkylmethyl, a 2,2-(alkylenedioxy)ethyl or a group represented by the formula:



wherein the ring A represents a benzene ring or a heterocyclic ring;  $(R^6)$ s are the same as or different from each other and each represents hydrogen, a halogen atom, hydroxyl group, nitrile group, a  $C_{1-6}$  alkyl group, a  $C_{3-8}$  cycloalkyl group, a  $C_{1-6}$  alkoxy group, a  $C_{1-6}$  alkoxyalkoxy group, an aryloxy group, an aralkyloxy group, a halogeno  $C_{1-6}$  alkyl group, a hydroxy  $C_{1-6}$  alkyl group, a cyano  $C_{1-6}$  alkyl group, a halogeno  $C_{1-6}$  alkoxy group, a hydroxy  $C_{1-6}$  alkoxy group, a cyano  $C_{1-6}$  alkoxy group, a lower acyl group, nitro group, an optionally substituted amino group, an optionally substituted amide group, mercapto group or a  $C_{1-6}$  thioalkoxy group, and two of the  $R^6$  may together form an aliphatic ring, an aromatic ring, a heterocyclic ring or an alkylenedioxy ring; and q is 0 or an integer from 1 to 5.

2. The compound according to Claim 1, a pharmacologically acceptable salt thereof or hydrates thereof, wherein  $R^1$  is represented by the formula:




in which  $R^{3a}$  and  $R^{3b}$  are the same as or different from each other

3. The compound according to Claim 2, a pharmacologically acceptable salt thereof or hydrates thereof, wherein R<sup>3a</sup> and R<sup>3b</sup> are methoxy groups.

5. The compound according to Claim 1, a pharmacologically acceptable salt thereof or hydrates thereof, wherein m is 1.

6. The compound according to Claim 1, a pharmacologically acceptable salt thereof or hydrates thereof, wherein R<sup>2</sup> is a group represented by the formula:



7. The compound according to Claim 6, a pharmacologically acceptable salt thereof or hydrates thereof, wherein the ring A is a benzene ring.

9. The compound according to Claim 6, a pharmacologically acceptable salt thereof or hydrates thereof, wherein q is an

integer of 1 or 2.

10. The compound according to Claim 1, a pharmacologically acceptable salt thereof or hydrates thereof, which is the one selected from:

1-benzyl-4-[(5,6-dimethoxy-2-chloro-1-indanon)-1-yl]methylnpiperidine,

1-benzyl-4-[(5,6-dimethoxy-2-bromo-1-indanon)-2-yl]methylnpiperidine,

1-benzyl-4-[(5,6-dimethoxy-2-iodo-1-indanon)-2-yl]methylnpiperidine,

1-benzyl-4-[(5,6-dimethoxy-2-hydroxy-1-indanon)-2-yl]methylnpiperidine,

1-benzyl-4-[(5,6-dimethoxy-2-methyl-1-indanon)-2-yl]methylnpiperidine,

1-benzyl-4-[(5,6-dimethoxy-2-ethyl-1-indanon)-2-yl]methylnpiperidine,

1-benzyl-4-[(5,6-dimethoxy-2-azido-1-indanon)-2-yl]methylnpiperidine,

1-benzyl-4-[(5,6-dimethoxy-2-amino-1-indanon)-2-yl]methylnpiperidine,

1-benzyl-4-[(5,6-dimethoxy-2-methylamino-1-indanon)-2-yl]methylnpiperidine,

1-benzyl-4-[(5,6-dimethoxy-2-dimethylamino-1-indanon)-2-yl]methylnpiperidine,

1-benzyl-4-[(5,6-dimethoxy-2-acetamide-1-indanon)-2-yl]methylnpiperidine,

1-benzyl-4-[(5,6-dimethoxy-2-methanesulfonamide-1-indanon)-2-yl]methylpiperidine,

3-(1-benzylpiperidin-4-yl)-2-chloro-1-(2,3,4,5-tetrahydro-1H-1-benzoazepin-8-yl)-1-propanone,

3-(1-benzylpiperidin-4-yl)-2,2-dichloro-1-(2,3,4,5-tetrahydro-1H-1-benzoazepin-8-yl)-1-propanone,

5,7-dihydro-3-{1-chloro-2-[(1-(phenylmethyl)-4-piperidinyl)ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisooxazol-6-one,

5,7-dihydro-3-{1,1-dichloro-2-[(1-(phenylmethyl)-4-piperidinyl)ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisooxazol-6-one,

1-(2-methyl-6-benzothiazolyl)-3-[1-(phenylmethyl)-4-piperidinyl]-2-chloro-1-propanone, and

1-(2-methyl-6-benzothiazolyl)-3-[1-(phenylmethyl)-4-piperidinyl]-2,2-dichloro-1-propanone.

11. A medicament comprising the compound according to Claim 1, a pharmacologically acceptable salt thereof or hydrates thereof as an active element.

12. The medicament according to Claim 11, which is an acetylcholinesterase inhibitor.

13. A medicament according to Claim 11, which is an agent for treating, preventing or ameliorating various types of senile dementia, cerebrovascular dementia or attention deficit hyperactivity disorder.

14. The medicament according to Claim 13, wherein the

various types of senile dementia is Alzheimer-type senile dementia.

15. A medical composition comprising a pharmacologically effective amount of the compound according to Claim 1, a pharmacologically acceptable salt thereof or hydrates thereof and a pharmacologically acceptable carrier.

16. A method of preventing, treating or ameliorating diseases against which the inhibition of an acetylcholinesterase is effective, by administering a pharmacologically effective amount of the compound according to Claim 1, a pharmacologically acceptable salt thereof or hydrates thereof to a patient.

17. A method of treating, preventing or ameliorating various types of senile dementia, cerebrovascular dementia or attention deficit hyperactivity disorder, by administering a pharmacologically effective amount of the compound according to Claim 1, a pharmacologically acceptable salt thereof or hydrates thereof to a patient.

18. Use of the compound according to claim 1, a pharmacologically acceptable salt thereof or hydrates thereof for producing an agent for preventing, treating or ameliorating diseases against which the inhibition of an acetylcholinesterase is effective.

19. Use of the compound according to Claim 1, a pharmacologically acceptable salt thereof or hydrates thereof for producing an acetylcholinesterase inhibitor.

20. Use of the compound according to Claim 1, a pharmacologically acceptable salt thereof or hydrates thereof for producing an agent for preventing, treating or ameliorating various types of senile dementia, cerebrovascular dementia or attention deficit hyperactivity disorder.



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☐ FADED TEXT OR DRAWING

☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☒ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**